Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem ; 21(17): 5373-82, 2013 Sep 01.
Article in English | MEDLINE | ID: mdl-23849205

ABSTRACT

Molecular probe tool compounds for the Sphingosine 1-phosphate receptor 2 (S1PR2) are important for investigating the multiple biological processes in which the S1PR2 receptor has been implicated. Amongst these are NF-κB-mediated tumor cell survival and fibroblast chemotaxis to fibronectin. Here we report our efforts to identify selective chemical probes for S1PR2 and their characterization. We employed high throughput screening to identify two compounds which activate the S1PR2 receptor. SAR optimization led to compounds with high nanomolar potency. These compounds, XAX-162 and CYM-5520, are highly selective and do not activate other S1P receptors. Binding of CYM-5520 is not competitive with the antagonist JTE-013. Mutation of receptor residues responsible for binding to the zwitterionic headgroup of sphingosine 1-phosphate (S1P) abolishes S1P activation of the receptor, but not activation by CYM-5520. Competitive binding experiments with radiolabeled S1P demonstrate that CYM-5520 is an allosteric agonist and does not displace the native ligand. Computational modeling suggests that CYM-5520 binds lower in the orthosteric binding pocket, and that co-binding with S1P is energetically well tolerated. In summary, we have identified an allosteric S1PR2 selective agonist compound.


Subject(s)
Pyrroles/chemistry , Receptors, Lysosphingolipid/agonists , Thioctic Acid/analogs & derivatives , Allosteric Regulation , Animals , Binding Sites , CHO Cells , Cricetinae , Cricetulus , High-Throughput Screening Assays , Humans , Kinetics , Ligands , Molecular Docking Simulation , Mutation , Protein Binding , Protein Structure, Tertiary , Pyrroles/metabolism , Receptors, Lysosphingolipid/genetics , Receptors, Lysosphingolipid/metabolism , Structure-Activity Relationship , Thioctic Acid/chemistry , Thioctic Acid/metabolism
3.
Bioorg Med Chem Lett ; 20(11): 3361-6, 2010 Jun 01.
Article in English | MEDLINE | ID: mdl-20434334

ABSTRACT

We identified a new benzothiophene containing Rho kinase inhibitor scaffold in an ultra high-throughput enzymatic activity screen. SAR studies, driven by a novel label-free cellular impedance assay, were used to derive 39, which substantially reduced intraocular pressure in a monkey model of glaucoma-associated ocular hypertension.


Subject(s)
Disease Models, Animal , Glaucoma/enzymology , Ocular Hypertension/enzymology , Protein Kinase Inhibitors/pharmacology , Thiophenes/pharmacology , rho-Associated Kinases/antagonists & inhibitors , Animals , Glaucoma/physiopathology , Haplorhini , HeLa Cells , Humans , Intraocular Pressure/drug effects , Ocular Hypertension/physiopathology
4.
Virology ; 366(2): 245-62, 2007 Sep 30.
Article in English | MEDLINE | ID: mdl-17580087

ABSTRACT

To assess the potential of native Envelope glycoprotein (Env) trimers as neutralizing antibody vaccines, we immunized guinea pigs with three types of VLPs and soluble gp120. Particles included "SOS-VLPs" (bearing disulfide-shackled functional trimers), "UNC-VLPs" (bearing uncleaved nonfunctional Env) and "naked VLPs" (bearing no Env). The SOS-VLPs were found to have a density of about 27 native trimers per particle, approximately twice that of live inactivated HIV-1 preparations. As immunogens, UNC- and SOS-VLP rapidly elicited anti-gp120 antibodies focused on the V3 loop and the gp120 coreceptor binding site. Reactivity to the gp41 immunodominant domain was absent in SOS-VLP sera, presumably because gp120-gp41 association is stabilized, effectively covering this epitope. Gp120-immune sera reacted with the receptor binding sites of gp120 and were less focused on the V3 loop. Some Env-VLP sera neutralized primary isolates at modest titers. The measurement of neutralization was found to be affected by the cell lines used. Depending on the assay particulars, non-Env specific antibodies in VLP sera could enhance infection, or nonspecifically neutralize. However, a neutralization assay using TZM-BL cells was essentially clear of these effects. We also describe a native trimer binding assay to confirm neutralization activity in a manner that completely eliminates nonspecific effects. Overall, our data suggests that Env-VLP sera were primarily focused on nonfunctional forms of Env on VLP surfaces, possibly gp120/gp41 monomers and not the trimers. Therefore, to make progress toward a more effective VLP-based vaccine, we will need to find ways to refocus the attention of B cells on native trimers.


Subject(s)
AIDS Vaccines/immunology , HIV Envelope Protein gp120/immunology , HIV-1/immunology , Animals , Cell Line , Guinea Pigs , HIV Antibodies/blood , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp41/immunology , Humans , Neutralization Tests
5.
J Virol ; 80(5): 2515-28, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16474158

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies are thought be distinguished from nonneutralizing antibodies by their ability to recognize functional gp120/gp41 envelope glycoprotein (Env) trimers. The antibody responses induced by natural HIV-1 infection or by vaccine candidates tested to date consist largely of nonneutralizing antibodies. One might have expected a more vigorous neutralizing response, particularly against virus particles that bear functional trimers. The recent surprising observation that nonneutralizing antibodies can specifically capture HIV-1 may provide a clue relating to this paradox. Specifically, it was suggested that forms of Env, to which nonneutralizing antibodies can bind, exist on virus surfaces. Here, we present evidence that HIV-1 particles bear nonfunctional gp120/gp41 monomers and gp120-depleted gp41 stumps. Using a native electrophoresis band shift assay, we show that antibody-trimer binding predicts neutralization and that the nonfunctional forms of Env may account for virus capture by nonneutralizing antibodies. We hypothesize that these nonfunctional forms of Env on particle surfaces serve to divert the antibody response, helping the virus to evade neutralization.


Subject(s)
HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp41/immunology , HIV-1/immunology , Animals , Antibodies, Monoclonal/immunology , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Electrophoretic Mobility Shift Assay , Enzyme-Linked Immunosorbent Assay , HIV Antibodies/immunology , HIV Envelope Protein gp120/chemistry , HIV Envelope Protein gp120/physiology , HIV Envelope Protein gp160/chemistry , HIV Envelope Protein gp160/immunology , HIV Envelope Protein gp160/physiology , HIV Envelope Protein gp41/chemistry , HIV Envelope Protein gp41/physiology , HIV-1/chemistry , HIV-1/physiology , Humans , Mice , Microscopy, Immunoelectron , Neutralization Tests , Virion/immunology
6.
J Virol ; 77(10): 5678-84, 2003 May.
Article in English | MEDLINE | ID: mdl-12719560

ABSTRACT

We previously described a human immunodeficiency virus type 1 (HIV-1) envelope mutant that introduces a disulfide bridge between the gp120 surface proteins and gp41 transmembrane proteins (J. M. Binley, R. W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D. J. Anselma, P. J. Maddon, W. C. Olson, and J. P. Moore, J. Virol. 74:627-643, 2000). Here we produced pseudovirions bearing the mutant envelope and a reporter gene to examine the mutant's infectious properties. These pseudovirions attach to cells expressing CD4 and coreceptor but infect only when triggered with reducing agent, implying that gp120-gp41 dissociation is necessary for infection. Further studies suggested that virus entry was arrested after CD4 and coreceptor engagement. By measuring the activities of various entry inhibitors against the arrested intermediate, we found that gp120-targeting inhibitors typically act prior to virus attachment, whereas gp41 inhibitors are able to act postattachment. Unexpectedly, a significant fraction of antibodies in HIV-1-positive sera neutralized virus postattachment, suggesting that downstream fusion events and structures figure prominently in the host immune response. Overall, this disulfide-shackled virus is a unique tool with potential utility in vaccine design, drug discovery, and elucidation of the HIV-1 entry process.


Subject(s)
Disulfides/metabolism , HIV Envelope Protein gp120/metabolism , HIV Envelope Protein gp41/metabolism , HIV-1/pathogenicity , Virion/pathogenicity , Cell Line , Disulfides/chemistry , Dithiothreitol/pharmacology , HIV Antibodies/blood , HIV Antibodies/immunology , HIV Envelope Protein gp120/chemistry , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp41/chemistry , HIV Envelope Protein gp41/genetics , HIV Infections/virology , HIV-1/genetics , Humans , Membrane Fusion , Neutralization Tests , Oxidation-Reduction , Receptors, CCR5/metabolism , Reducing Agents/pharmacology , Virion/genetics
7.
Cancer Biol Ther ; 1(5): 502-8, 2002.
Article in English | MEDLINE | ID: mdl-12496477

ABSTRACT

BRCA1 is a tumor suppressor gene and germ line mutations account for the majority of familial cases of breast and ovarian cancer. There is mounting evidence that BRCA1 functions in DNA repair and transcriptional regulation. A major hurdle to dissect the role of BRCA1 is the lack of molecular reagents to carry out biochemical and genetic experiments. Therefore, we used random mutagenesis of the C-terminus of BRCA1 (aa 1560-1863) to generate temperature-sensitive (TS) mutants in transcription activation. We obtained 11 TS mutants in transcription that localized primarily to the hydrophobic core of the BRCT-N domain of BRCA1. One of the mutants, H1686Q, also displayed temperature-dependent transcription activation in human cells. These conditional mutants represent valuable tools to assess the role of BRCA1 in transcription activation.


Subject(s)
BRCA1 Protein/chemistry , Mutation , Transcriptional Activation , Amino Acid Sequence , BRCA1 Protein/genetics , BRCA1 Protein/physiology , Breast Neoplasms/etiology , Female , Humans , Models, Molecular , Ovarian Neoplasms/etiology , Protein Structure, Secondary , Protein Structure, Tertiary , Recombinant Fusion Proteins/metabolism , Saccharomyces cerevisiae/genetics , Temperature , Transcription, Genetic
8.
J Virol ; 76(6): 2606-16, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11861826

ABSTRACT

In virus-infected cells, the envelope glycoprotein (Env) precursor, gp160, of human immunodeficiency virus type 1 is cleaved by cellular proteases into a fusion-competent gp120-gp41 heterodimer in which the two subunits are noncovalently associated. However, cleavage can be inefficient when recombinant Env is expressed at high levels, either as a full-length gp160 or as a soluble gp140 truncated immediately N-terminal to the transmembrane domain. We have explored several methods for obtaining fully cleaved Env for use as a vaccine antigen. We tested whether purified Env could be enzymatically digested with purified protease in vitro. Plasmin efficiently cleaved the Env precursor but also cut at a second site in gp120, most probably the V3 loop. In contrast, a soluble form of furin was specific for the gp120-gp41 cleavage site but cleaved inefficiently. Coexpression of Env with the full-length or soluble form of furin enhanced Env cleavage but also reduced Env expression. When the Env cleavage site (REKR) was mutated in order to see if its use by cellular proteases could be enhanced, several mutants were found to be processed more efficiently than the wild-type protein. The optimal cleavage site sequences were RRRRRR, RRRRKR, and RRRKKR. These mutations did not significantly alter the capacity of the Env protein to mediate fusion, so they have not radically perturbed Env structure. Furthermore, unlike that of wild-type Env, expression of the cleavage site mutants was not significantly reduced by furin coexpression. Coexpression of Env cleavage site mutants and furin is therefore a useful method for obtaining high-level expression of processed Env.


Subject(s)
Endopeptidases/metabolism , Gene Products, env/metabolism , HIV-1/metabolism , Protein Precursors/metabolism , Subtilisins/metabolism , Furin , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp120/metabolism , HIV Envelope Protein gp160/genetics , HIV Envelope Protein gp160/metabolism , HIV Envelope Protein gp41/genetics , HIV Envelope Protein gp41/metabolism , HIV-1/genetics , HIV-1/pathogenicity , HeLa Cells , Humans , Protein Precursors/genetics , Recombinant Proteins/metabolism , Subtilisins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...